Delayed Bolsas y Mercados Espanoles - 05/16 11:38:00 am
70.48
EUR
+1.64%
Quotes 5-day view Delayed Bolsas Y Mercados Espanol…
05/10/2022
05/11/2022
05/12/2022
05/13/2022
05/16/2022
Date
67.18(c)
68.34(c)
67.24(c)
69.34(c)
70.48 Last
80 153
44 142
57 490
40 790
37 805 Volume
-0.53% +1.73% -1.61% +3.12% +1.64% Change
Estimated financial data (e) EUR USD
Sales 2022
220 M 229 M 229 M
Net income 2022
79,0 M 82,2 M 82,2 M
Net cash position 2022
217 M 225 M 225 M
P/E ratio 2022
16,1x
Yield 2022
0,80%
Sales 2023
259 M 269 M 269 M
Net income 2023
116 M 120 M 120 M
Net cash position 2023
302 M 315 M 315 M
P/E ratio 2023
11,5x
Yield 2023
0,75%
Capitalization
1 269 M 1 321 M 1 321 M
EV / Sales 2022
4,78x
EV / Sales 2023
3,74x
Nbr of Employees
477
Free-Float
71,8%
Pharma Mar, S.A. specializes in research and development into marine-origin medicines. The group also offers tools to treat cancer. Net sales break down by family of products as follows:
- antitumor drugs (93.3%). Pharma Mar also offers medicines for the treatment of immune and viral diseases. At the end of 2019, the group had a portfolio of 6 products in clinical development phase (including 1 in phase III, 2 in...
Ratings of Pharma Mar,S.A.
All news about PHARMA MAR,S.A.
04/29 TRANSCRIPT : Pharma Mar, S.A., Q1 2022 Earnings Call, Apr 29, 2022CI
04/28 PHARMA MAR,S.A. : 1st quarter resultsCO
03/09 TRANSCRIPT : Pharma Mar, S.A. - Special CallCI
03/07 PharmaMar receives the first commercial milestone payment from Jazz Pharmaceuticals for.. AQ
03/01 TRANSCRIPT : Pharma Mar, S.A., 2021 Earnings Call, Mar 01, 2022CI
02/28 Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
02/28 PHARMA MAR S A : Annual Report PharmaMar 2021PU
02/28 PHARMA MAR S A : Separate Financial Statements 2021PU
02/28 PHARMA MAR S A : Non-financial Information Statement 2021PU
02/28 Spain's PharmaMar raises dividend despite 32% drop in 2021 profit RE
02/28 Spain's PharmaMar 2021 net profit falls 32% RE
01/12 Life Science Alliance journal publishes results of plitidepsin in patients with COVID-1.. AQ
01/11 Pharma Mar, S.A. Announces Publication of an Article in the Life Science Alliance Journ.. CI
01/11 PharmaMar shares soar after drug study suggests efficacy against Omicron RE
01/11 Pharma Mar Surges 9% as COVID-19 Treatment Shows Efficacy Against Omicron MT
News in other languages on PHARMA MAR,S.A.
04/29 EN DIRECTO DESDE LOS MERCADOS : Merlin, BBVA, Indra, Pharma, CaixaBank, Apple, Amazon, Twi..04/29 BOLSA DE MADRID : ¿China como apoyo?04/04 BOLSA DE MADRID : "Nuestras materias primas, vuestro problema"03/04 EN DIRECTO DESDE LOS MERCADOS : ArcelorMittal, Cellnex, Telefónica, Honda, BBVA, Crédit Su..03/04 BOLSA DE MADRID : Terror nuclear
Analyst Recommendations on PHARMA MAR,S.A.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends PHARMA MAR,S.A.
Short Term Mid-Term Long Term Trends Bearish Bullish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
69,34 €
Average target price
79,42 €
Spread / Average Target
14,5%
Please enable JavaScript in your browser's settings to use dynamic charts.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
